Survey on target treatment for lung cancer
Published: 2007-07-06 06:57:00
Updated: 2007-07-06 06:57:00
Four out of 10 doctors said a target agent for lung cancer would replace the conventional chemotherapeutic agents within the next five years, according to a recent survey conducted by AstraZeneca Korea (AZ Korea) which marked its seven-year launching of Iressa (gefinitib).
The survey of 162 sp...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.